Lianne Singer
Respirologist who is Medical Director of the Toronto Lung Transplant Program, with research interests in quality of life, telemedicine and clinical trials in lung transplantation.
As of . Primary source: UHN Research profile.
Summary
According to her UHN Research profile, Lianne Singer is Medical Director of the Toronto Lung Transplant Program at University Health Network, Clinical Trials Director of the Multi-Organ Transplant Program, and a Professor in the Department of Medicine at the University of Toronto. Her stated research interests are health-related quality of life in advanced lung disease and lung transplantation, telemedicine in lung transplantation, and clinical trials.
Ranking method and caveats
Methodology for the researcher ranking
- Query: OpenAlex works of type article or review whose title or abstract contains "chronic lung allograft dysfunction" or "restrictive allograft syndrome", or "bronchiolitis obliterans" together with lung transplant terms. Retracted works and meeting-abstract supplements are removed.
- Window and date: works published 2016-10-11 to 2026-10-10; counts retrieved 2026-10-10 (2,461 works, 8,698 author profiles after merging).
- Counting: the rank is by total citations of the author's papers (whole counting). Fractional counts, first or last author papers and counts without the two 2019 ISHLT consensus papers are shown on each record.
- Identity: authors are identified by OpenAlex author identifier and ORCID. Duplicate profiles were merged by identical ORCID, or by compatible name plus shared institution. Only the top 30 entries were checked by hand.
- Rising researchers: a separate numbered list ordered by citations in the 5 years from 2021-10-11, for authors whose first paper in the corpus is dated 2019 or later and who have at least 5 papers in that window. It is a proxy, not a measure of career stage.
- Caveats: the corpus includes papers only partly about CLAD; consensus papers inflate some totals; recent papers are under-cited; author identifiers can be wrong; citations measure attention, not quality or clinical skill.
Details
- role
- Medical Director, Toronto Lung Transplant Program; Clinical Trials Director, Multi-Organ Transplant Program; Professor of Medicine (University of Toronto)
- affiliation
- Toronto Lung Transplant Program, University Health Network; University of Toronto
- citation rank 10y
- 6 of 8,698 author profiles (top 100 listed)
- papers 10y
- 84
- fractional papers 10y
- 6.74
- citations 10y
- 2222
- fractional citations 10y
- 153
- lead author papers 10y
- 4
- citations excluding two ishlt2019consensus papers
- 969
- rank excluding two ishlt2019consensus papers
- 10
- ranking retrieved
- 2026-10-10
- orcid
- 0000-0002-2693-8676
- openalex author id
- A5033864764
- merged open alex profiles
- 3
- affiliation basis
- unverified; OpenAlex lists "University Health Network" on the most recent corpus paper (2026). Not confirmed as current.
Sources and links
- UHN Research profile (primary)
- OpenAlex author profile (ranking source)
- ORCID record
- Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT (The Journal of Heart and Lung Transplantation, 2019); 952 citations; DOI 10.1016/j.healun.2019.03.009
- Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome―A consensus report from the Pulmonary Council of the ISHLT (The Journal of Heart and Lung Transplantation, 2019); 301 citations; DOI 10.1016/j.healun.2019.03.008
- Most-cited CLAD paper in corpus: Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system (The Journal of Heart and Lung Transplantation, 2020); 77 citations; DOI 10.1016/j.healun.2020.04.012
- Most-cited CLAD paper in corpus: The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation (American Journal of Transplantation, 2020); 51 citations; DOI 10.1111/ajt.15561
- Most-cited CLAD paper in corpus: Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction (American Journal of Transplantation, 2022); 30 citations; DOI 10.1111/ajt.17108
Related
Links from this record
- member of: Toronto Lung Transplant Program (University Health Network)
- author: Phenotyping CLAD after single lung transplant: Limits and prognostic assessment of the 2019 ISHLT classification system
- author: Eosinophils in transbronchial biopsies: a predictor of chronic lung allograft dysfunction and reduced survival after lung transplantation — a retrospective single‐center cohort study.
- author: Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion
- author: Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement
- author: The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation.
- author: Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction
- author: Bronchoalveolar lavage cytokine-based risk stratification of clinically-stable lung transplant recipients with undefined rejection: Further insights from a follow-up investigation
- author: Oesophageal stasis is a risk factor for chronic lung allograft dysfunction and allograft failure in lung transplant recipients.
- author: Prognosis and Risks for Probable Chronic Lung Allograft Dysfunction: A Prospective Multicenter Study
- author: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment: A consensus report from the Pulmonary Council of the ISHLT
- author: Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome: A consensus report from the Pulmonary Council of the ISHLT
- author: Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system
Linked from (derived)
- coauthor: Phenotyping CLAD after single lung transplant: Limits and prognostic assessment of the 2019 ISHLT classification system
- coauthor: Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement
- coauthor: Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction
- coauthor: Bronchoalveolar lavage cytokine-based risk stratification of clinically-stable lung transplant recipients with undefined rejection: Further insights from a follow-up investigation
- coauthor: Prognosis and Risks for Probable Chronic Lung Allograft Dysfunction: A Prospective Multicenter Study
Known gaps in this record
- current funding
- ORCID identifier
- academic rank (the profile text says Associate Professor in the biography and Professor in the appointments list)
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.